The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Can Peripheral Spondyloarthritis Be Reversed?

Can Peripheral Spondyloarthritis Be Reversed?

November 18, 2018 • By Ruth Jessen Hickman, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Agenturfotografin / shutterstock.com

Agenturfotografin / shutterstock.com

Currently, treatment options for patients with peripheral spondyloarthritis, which includes psoriatic arthritis and non-psoriatic types, are limited. Philippe Carron, MD, Department of Rheumatology, Ghent University Hospital, Belgium, says, “One of the problems we encounter in the daily management of peripheral spondyloarthritis is that we have no other therapeutic options in patients refractory to NSAIDs [non-steroidal anti-inflammatory drugs], sulfasalazine and methotrexate. Most of these patients are young and experience a high burden of disease. We know that TNF inhibitors are efficient, but they are not reimbursed unless there is concomitant psoriasis or sacroiliac involvement, which is not always present.”

You Might Also Like
  • Peripheral Manifestations of Spondyloarthritis
  • Subcutaneous Golimumab in Active Non-Radiographic Axial Spondyloarthritis
  • Adalimumab May Help Maintain Remission in Non-Radiographic Axial Spondyloarthritis
Explore This Issue
November 2018
Also By This Author
  • Granulomatosis with Polyangiitis Rates & Outcomes

The CRESPA Study

Dr. Carron is also the first author of a paper published in Arthritis & Rheumatology.1 The CRESPA study (clinical remission in peripheral spondyloarthritis) analyzed patients diagnosed with peripheral spondyloarthritis (as fulfilled by the Assessment of SpondyloArthritis International Society [ASAS] classification criteria) who had experienced symptoms for fewer than 12 weeks.1 The randomized, placebo-controlled phase was followed by an open-label phase from Weeks 24–48. The study included 60 patients, 40 of whom received 50 mg of the TNF inhibitor golimumab subcutaneously every four weeks until Week 20 and another 20 patients who received placebo.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Golimumab was stopped in patients in sustained clinical remission. This was defined as complete absence of peripheral arthritis, enthesitis and dactylitis at two consecutive visits (at Weeks 12, 24, 36 and 48). Patients with sustained disease activity at the end of Week 24 received 50 mg golimumab every four weeks through Week 48. In the open-label extension, patients restarted 50 mg golimumab for a total of 104 weeks if they developed a clinical relapse (at least one swollen joint plus enthesitis or dactylitis) after an initial remission. Those showing partial response (at least 40% improvement from baseline as defined by the Peripheral Spondyloarthritis Response Criteria) also received golimumab for the extension period.

Eighty-two percent of patients (49/60) achieved sustained clinical remission following induction of golimumab. Of the 49 responders, 30 were in remission by Week 24 and another 11 by Week 35; eight more were in remission by Week 40. No significant response occurred in placebo-treated patients, ruling out spontaneous remission. The researchers followed patients from a range of 23 months to five years after golimumab cessation. At that time, 53% of the responders (26 of 49) were still in sustained and drug-free remission.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The researchers also analyzed factors that predicted relapse after drug withdrawal. Both polyarticular disease and pre-existing psoriasis were strong predictors for relapse. In patients with psoriasis, the estimated odds for sustained drug-free remission was 80% lower (OR=0.2, 95% CI 0.06 to 0.65, P=0.008), and patients with polyarticular disease had odds 83% lower (OR=0.17, 95% CI 0.03 to 0.84, P=0.03) than for patients without polyarticular disease or psoriasis.

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Research Reviews, Spondyloarthritis Tagged With: TNF inhibitorsIssue: November 2018

You Might Also Like:
  • Peripheral Manifestations of Spondyloarthritis
  • Subcutaneous Golimumab in Active Non-Radiographic Axial Spondyloarthritis
  • Adalimumab May Help Maintain Remission in Non-Radiographic Axial Spondyloarthritis
  • Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis

About Ruth Jessen Hickman, MD

Ruth Jessen Hickman, MD, was born and raised in eastern Kentucky, where she first cultivated her love of literature, writing and personal narratives. She attended Kenyon college, where she received a Bachelor of Arts in philosophy, summa cum laude. She worked with individuals with psychiatric conditions and later in a neuroscience lab at the University of Illinois, Chicago, before graduating from Indiana University Medical School in 2011. Instead of pursuing clinical medicine, Ruth opted to build on her strength of clearly explaining medical topics though a career as a freelance medical writer, writing both for lay people and for health professionals. She writes across the biomedical sciences, but holds strong interests in rheumatology, neurology, autoimmune diseases, genetics, and the intersection of broader social, cultural and emotional contexts with biomedical topics. Ruth now lives in Bloomington, Ind., with her husband, son and cat. She can be contacted via her website at www.ruthjhickmanmd.com.

View more by this author»

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.